Literature DB >> 24787691

Preparation and properties of biocompatible PS-PEG/calcium phosphate nanospheres.

Qi Wang1, Peifeng Liu, Ying Sun, Tao Gong, Mingjie Zhu, Xun Sun, Zhirong Zhang, Yourong Duan.   

Abstract

A facile room-temperature method was used to prepare phosphatidylserine (PS)-poly(ethylene glycol) (PEG)/calcium phosphate (CaP) nanospheres (PS-poly(ethylene glycol) methyl ether/CaP nanospheres). Transmission electron microscopy (TEM) results confirmed that the PS-PEG/CaP porous nanospheres were spherical with a diameter of 8-12 nm. X-ray and thermo-gravimetric analysis (TGA) results also confirmed that the PS-PEG micelle was packed in the CaP shell. PS-PEG/CaP nanospheres exhibited little effect on the hemolysis, coagulation characteristics of blood and inflammatory response, demonstrating a negligible cytotoxicity response in LO2 liver cells. Experiments performed in zebrafish demonstrated that the PS-PEG/CaP nanospheres had a long circulatory residence time and did not induce apoptosis in zebrafish. Taken together, these results suggest that the PS-PEG/CaP nanospheres have great potential to be used as a drug carrier.

Entities:  

Keywords:  Biocompatible; biodistribution; cytotoxicity; drug carrier; nanospheres

Mesh:

Substances:

Year:  2014        PMID: 24787691     DOI: 10.3109/17435390.2014.911381

Source DB:  PubMed          Journal:  Nanotoxicology        ISSN: 1743-5390            Impact factor:   5.913


  7 in total

1.  Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer.

Authors:  Zelai He; Zengfang Shi; Wenjie Sun; Jing Ma; Junyong Xia; Xiangyu Zhang; Wenjun Chen; Jingwen Huang
Journal:  Tumour Biol       Date:  2015-12-22

Review 2.  What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine.

Authors:  María Cascallar; Sandra Alijas; Alba Pensado-López; Abi Judit Vázquez-Ríos; Laura Sánchez; Roberto Piñeiro; María de la Fuente
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

Review 3.  Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.

Authors:  Michael-Joseph Gorbet; Ashish Ranjan
Journal:  Pharmacol Ther       Date:  2019-12-19       Impact factor: 12.310

4.  Tumour targeted contrast enhanced ultrasound imaging dual-modal microbubbles for diagnosis and treatment of triple negative breast cancer.

Authors:  Min Bai; Yang Dong; Hui Huang; Hao Fu; Yourong Duan; Qi Wang; Lianfang Du
Journal:  RSC Adv       Date:  2019-02-15       Impact factor: 4.036

5.  Low toxicity and long circulation time of polyampholyte-coated magnetic nanoparticles for blood pool contrast agents.

Authors:  Qi Wang; Ming Shen; Tao Zhao; Yuanyuan Xu; Jiang Lin; Yourong Duan; Hongchen Gu
Journal:  Sci Rep       Date:  2015-01-14       Impact factor: 4.379

6.  Biocompatible and colloidally stabilized mPEG-PE/calcium phosphate hybrid nanoparticles loaded with siRNAs targeting tumors.

Authors:  Pei Gao; Xiangyu Zhang; Hongzhi Wang; Qinghong Zhang; He Li; Yaogang Li; Yourong Duan
Journal:  Oncotarget       Date:  2016-01-19

7.  Incorporation of drug efflux inhibitor and chemotherapeutic agent into an inorganic/organic platform for the effective treatment of multidrug resistant breast cancer.

Authors:  Yang Dong; Hongze Liao; Jian Yu; Hao Fu; Ke Gong; Qi Wang; Yourong Duan
Journal:  J Nanobiotechnology       Date:  2019-12-23       Impact factor: 10.435

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.